Dow Jones -- Pfizer Inc. (PFE) has decided not to proceed with a late-stage clinical trial of its antipsychotic drug Geodon in children with bipolar disorder, a controversial area for the drug.
Dow Jones -- Pfizer Inc. (PFE) has decided not to proceed with a late-stage clinical trial of its antipsychotic drug Geodon in children with bipolar disorder, a controversial area for the drug.